Importantly, our study sets a remarkable example of cancer plasticity that underlies melanoma primary resistance to drug therapies: upon BRAFi treatment, the resistance is accompanied by MAPK pathway activation, which triggers cell cycle progression and CDK2 activation (Lents et al, 2002). The gene discussed is CDK2; the disease is cancer.